image

Investors

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Archived Events
Wells Fargo Targeted Protein Degradation Virtual Summit
February 21, 2023 from 1:00 PM to 1:45 PM EST
View Webcast
Wells Fargo Targeted Protein Degradation Virtual Summit
February 21, 2023 from 8:00 AM to 8:45 AM EST
View Webcast
SVB Securities Global Biopharma Conference
February 15, 2023 from 4:20 PM to 5:00 PM EST
View Webcast
Piper Sandler 34th Annual Healthcare Conference
November 30, 2022 at 4:30 PM EST
View Webcast
2022 RBC Capital Markets Global Healthcare Conference
May 18, 2022 at 11:00 AM EDT
View Webcast
21st Annual Needham Virtual Healthcare Conference
April 11, 2022 at 2:15 PM EDT
View Webcast
2nd Guggenheim Targeted Protein Degradation Day
March 16, 2022 at 11:00 AM EDT
View Webcast
Corporate Presentations
Scientific Presentation
Print Page
Email Alerts
RSS Feeds
Contact IR